HLA Genotype and Carbamazepine‐Induced Cutaneous Adverse Drug Reactions: A Systematic Review

[1]  S. Tiamkao,et al.  HLA‐B*1502 Strongly Predicts Carbamazepine‐Induced Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Thai Patients with Neuropathic Pain , 2012, Pain practice : the official journal of World Institute of Pain.

[2]  Sang-Heon Cho,et al.  Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans , 2011, Epilepsy Research.

[3]  R. Jamal,et al.  Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. , 2011, Asian Pacific journal of allergy and immunology.

[4]  Q. Wang,et al.  Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland , 2011, Seizure.

[5]  B. Carleton,et al.  Phenotype Standardization for Immune‐Mediated Drug‐Induced Skin Injury , 2011, Clinical pharmacology and therapeutics.

[6]  Michael R. Johnson,et al.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. , 2011, The New England journal of medicine.

[7]  Chen-Yang Shen,et al.  Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. , 2011, The New England journal of medicine.

[8]  Limei Zhao,et al.  Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients , 2011, European Journal of Clinical Pharmacology.

[9]  S. Mallal,et al.  Drug hypersensitivity: pharmacogenetics and clinical syndromes. , 2011, The Journal of allergy and clinical immunology.

[10]  Yusuke Nakamura,et al.  Genome-wide association study identifies HLA-A ∗ 3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population , 2022 .

[11]  S. Murad,et al.  Association of HLA‐B*1502 allele with carbamazepine‐induced toxic epidermal necrolysis and Stevens–Johnson syndrome in the multi‐ethnic Malaysian population , 2011, International journal of dermatology.

[12]  P. Wiffen,et al.  Carbamazepine for acute and chronic pain in adults. , 2011, The Cochrane database of systematic reviews.

[13]  C. Sotozono,et al.  HLA‐B*1511 is a risk factor for carbamazepine‐induced Stevens‐Johnson syndrome and toxic epidermal necrolysis in Japanese patients , 2010, Epilepsia.

[14]  P. Kwan,et al.  Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China , 2010, Epilepsy & Behavior.

[15]  S. Tiamkao,et al.  Association between HLA‐B*1502 and carbamazepine‐induced severe cutaneous adverse drug reactions in a Thai population , 2010, Epilepsia.

[16]  V. Shotelersuk,et al.  HLA‐B* 1502 screening: Time to clinical practice , 2010, Epilepsia.

[17]  M. Muramatsu,et al.  HLA Class I markers in Japanese patients with carbamazepine‐induced cutaneous adverse reactions , 2010, Epilepsia.

[18]  C. Joshi,et al.  Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. , 2009, Indian journal of dermatology, venereology and leprology.

[19]  P. Williamson,et al.  Methodological quality of pharmacogenetic studies: Issues of concern , 2008, Statistics in medicine.

[20]  K. Suphapeetiporn,et al.  Carbamazepine and phenytoin induced Stevens‐Johnson syndrome is associated with HLA‐B*1502 allele in Thai population , 2008, Epilepsia.

[21]  C. Sotozono,et al.  HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2008, Pharmacogenomics.

[22]  Howard L McLeod,et al.  Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. , 2008, Pharmacogenomics.

[23]  M. Muramatsu,et al.  Human leukocyte antigen genotypes in carbamazepine‐induced severe cutaneous adverse drug response in Japanese patients , 2008, The Journal of dermatology.

[24]  P. Kwan,et al.  Association of HLA-B*1502 allele and carbamazepine- induced severe adverse cutaneous drug reaction among Asians, a review , 2008 .

[25]  T. Shiohara,et al.  HLA-B allele associations with certain drugs are not confirmed in Japanese patients with severe cutaneous drug reactions. , 2008, Acta dermato-venereologica.

[26]  Yuan-Tsong Chen,et al.  Human leukocyte antigens and drug hypersensitivity , 2007, Current opinion in allergy and clinical immunology.

[27]  P. Kwan,et al.  Association between HLA‐B*1502 Allele and Antiepileptic Drug‐Induced Cutaneous Reactions in Han Chinese , 2007, Epilepsia.

[28]  M. Pirmohamed,et al.  Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. , 2007, The Journal of allergy and clinical immunology.

[29]  David F. Smith,et al.  The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial , 2007, The Lancet.

[30]  M. Pirmohamed,et al.  HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. , 2006, Pharmacogenomics.

[31]  S. Jee,et al.  Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions , 2006, Pharmacogenetics and genomics.

[32]  M. Schumacher,et al.  A marker for Stevens-Johnson syndrome …: ethnicity matters , 2006, The Pharmacogenomics Journal.

[33]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[34]  J. Roujeau,et al.  Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? , 2000, Archives of dermatology.

[35]  S. Aylett,et al.  Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins , 1999, Postgraduate medical journal.

[36]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[37]  G. Chelvanayagam.  A roadmap for HLA-A, HLA-B, and HLA-C peptide binding specificities , 1996, Immunogenetics.

[38]  R. Stern,et al.  Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. , 1996, The New England journal of medicine.

[39]  L. Hughes-Davies,et al.  Severe adverse cutaneous reactions to drugs. , 1995, The New England journal of medicine.